NEKTAR THERAPEUTICS — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2021-02-02

Reporting Person: Labrucherie Gil M (SVP, COO & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-02	Common Stock	M	50000	$8.80	Acquired	316973	Direct
2021-02-02	Common Stock	S	41135	$19.97	Disposed	275838	Direct
2021-02-02	Common Stock	S	6932	$20.96	Disposed	268906	Direct
2021-02-02	Common Stock	S	1933	$21.66	Disposed	266973	Direct
2021-02-03	Common Stock	M	25000	$8.80	Acquired	291973	Direct
2021-02-03	Common Stock	M	25000	$8.80	Acquired	316973	Direct
2021-02-03	Common Stock	S	50000	$19.61	Disposed	266973	Direct
2021-02-04	Common Stock	M	50000	$8.80	Acquired	316973	Direct
2021-02-04	Common Stock	S	50000	$19.81	Disposed	266973	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-02	Stock Option	$8.80	M	50000	Disposed	2021-02-05	Common Stock (50000)	Direct
2021-02-03	Stock Option	$8.80	M	25000	Disposed	2021-02-05	Common Stock (25000)	Direct
2021-02-03	Stock Option	$8.80	M	25000	Disposed	2021-02-05	Common Stock (25000)	Direct
2021-02-04	Stock Option	$8.80	M	50000	Disposed	2021-02-05	Common Stock (50000)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021.

F2: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

F3: This transaction was executed in multiple trades at prices ranging from $19.55 to $20.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F4: This transaction was executed in multiple trades at prices ranging from $20.56 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F5: This transaction was executed in multiple trades at prices ranging from $21.57 to $21.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F6: This transaction was executed in multiple trades at prices ranging from $19.30 to $19.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F7: This transaction was executed in multiple trades at prices ranging from $19.50 to $20.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.